Research Topics
Species | R T SilverSummaryAffiliation: Cornell University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosisRichard T Silver
Myeloproliferative Disease Center, Division of Hematology Oncology, Weill Cornell Medical Center, New York, NY, USA
Expert Rev Hematol 6:49-58. 2013..In hypercellular primary myelofibrosis, rIFN-α has restored normal blood counts, reduced splenomegaly and induced morphologic marrow remissions. This article highlights our current use of rIFN-α in MPNs...- Treatment of polycythemia vera with imatinib mesylateRichard T Silver
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065 4896, USA
Leuk Res 36:156-62. 2012..Therefore, we believe there may be a role for IM in patients with these characteristics whose disease cannot be controlled by, or as an alternative to, other myelosuppressive treatments... 
Long-term effects of the treatment of polycythemia vera with recombinant interferon-alphaRichard T Silver
Division of Hematology Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
Cancer 107:451-8. 2006..Evidence is presented indicating that rIFN alpha effectively reduces PHL requirements, thrombocythemia, splenomegaly, and thrombohemorrhagic events. It is an effective drug for treating PV with acceptable toxicity...- The third International Congress on Myeloproliferative and Myelodysplastic SyndromesR T Silver
Weill Medical College of Cornell University, 1300 York Ave Box 581, New York, NY 10021 4896, USA
Leuk Res 31:11-7. 2007..He reviewed the molecular steps in the formation of the Philadelphia chromosome and some of the newly described mutations leading to resistance to chemotherapy (see Section 4)... - Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013Richard T Silver
Weill Medical College of Cornell University, Division of Hematology Oncology, 525 E 68th St Box 581, New York, NY 10021, USA
Leuk Lymphoma 44:39-48. 2003..01) using a landmark analysis at 18 months. This intermittent schedule of rIFNalpha-2b/ara-C has a high response rate in patients with CML with acceptable toxicity... - Chronic myeloid leukemiaRichard T Silver
Weill Cornell Medical College, 525 East 68th Street, Box 581, New York, NY 10021, USA
Hematol Oncol Clin North Am 17:1159-73, vi-vii. 2003.... - Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylateRichard T Silver
New York Presbyterian Hospital Weill Cornell Medical Center, 1300 York Avenue, Box 581, New York, NY 10021, USA
Curr Hematol Malig Rep 2:43-6. 2007..Used as single agents, each produces lasting remissions in about 75% of patients with polycythemia vera. Of significance, change in JAK2 expression has been reported after treatment with both agents... - JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapyRichard T Silver
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, New York, NY 10065 4896, USA
Leuk Res 35:177-82. 2011..The JAK2(V617F) allele burden did not change significantly in treated patients with serial JAK2 analyses... 
Predictive value of in vitro mutation data to guide second-generation tyrosine kinase inhibitor selection: ready for prime time?Richard T Silver
Weill Cornell Medical College, Department of Medicine, Division of Hematology and Medical Oncology, New York, New York 10065 4896, USA
Oncologist 16:554-8. 2011..Selection of a second-generation tyrosine kinase inhibitor should therefore be based upon its toxicity profile in conjunction with the patient's comorbidities and the practitioner's experience...- Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary reportRichard T Silver
Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, 1305 York Avenue, New York, NY 10021, USA
Blood 117:6669-72. 2011..Improvement in marrow morphology occurred in 4. Toxicity was acceptable. These results, with documented marrow reversion because of interferon treatment, warrant expanded evaluation... - The second international congress on myeloproliferative and myelodysplastic syndromesR T Silver
Weill-Cornell Medical Center, 1300 York Ave-Box 34, New York, NY 10021 4896, USA
Leuk Res 28:979-85. 2004.... - Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosisEllinor I Peerschke
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 11777, USA
Am J Clin Pathol 127:422-8. 2007..These studies suggest that CPA platelet deposition patterns may provide novel insight into global platelet function during hemodynamic flow... - Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylateRichard T Silver
New York Presbyterian-Weill Cornell Medical Center, 1300 York Avenue, Box 581, New York, NY 10021, USA
Curr Hematol Rep 4:235-7. 2005..Two new drugs are now available, interferon and imatinib mesylate, which may alter the course of this disease. Used as single agents, each produces lasting remissions in about 75% of the cases... - Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013M L Hensley
Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, and New York Presbyterian Hospital, New York, NY 10021, USA
J Clin Oncol 18:1301-8. 2000..The purpose of this study was to identify predictors for the development of severe neuropsychiatric toxicity in CML patients receiving rIFNalpha2b-based therapy... - Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemiaG J Roboz
Division of Hematology and Oncology, Weill Medical College of Cornell University and The New York Presbyterian Hospital, New York, NY 10021, USA
Leuk Lymphoma 43:1951-5. 2002..In conclusion, in patients with relapsed/refractory AML, gemtuzumab ozogamicin has a comparable response rate to single-agent chemotherapy and may offer a more favorable toxicity profile... - The blast phase of chronic myeloid leukaemiaRichard T Silver
Department of Medicine, Division of Hematology and Medical Oncology, Leukemia and Myeloproliferative Center, Weill Cornell Medical College, 525 East 68th Street, Box 581, Payson Pavilion, 3rd Floor, New York, NY 10065, USA
Best Pract Res Clin Haematol 22:387-94. 2009..For those patients who achieve a remission following the use of one of the aforementioned drugs, bone marrow transplantation is recommended... - A study of a reduced-intensity conditioning regimen followed by allogeneic stem cell transplantation for patients with hematologic malignancies using Campath-1H as part of a graft-versus-host disease strategyTsiporah Shore
Weill Medical College of Cornell University New York Presbyterian Hospital, New York, New York 10021, USA
Biol Blood Marrow Transplant 12:868-75. 2006.... - Treatment of polycythemia veraRichard T Silver
Division of Hematology Oncology, New York Presbyterian Weill Cornell Medical Center, New York, New York 10021 4873, USA
Semin Thromb Hemost 32:437-42. 2006..Clearly, the best treatment for patients with PV is still sought. Perhaps more explicit exploitation of the JAK2 abnormality found in PV (and other myeloproliferative diseases) may provide more effective agents in the future... - Ex vivo evaluation of erythrocytosis-enhanced platelet thrombus formation using the cone and plate(let) analyzer: effect of platelet antagonistsEllinor I B Peerschke
Department of Pathology, Weill Medical College of Cornell University, New York, NY, USA
Br J Haematol 127:195-203. 2004..These findings support the use of CPA for ex vivo evaluation of the contribution of RBC to platelet function and its inhibition under physiological shear conditions... - The emergence of Ph-, trisomy -8+ cells in patients with chronic myeloid leukemia treated with imatinib mesylateEric Feldman
The Leukemia and Myeloproliferative Center, Weill Medical College of Cornell University, New York, NY, USA
Exp Hematol 31:702-7. 2003..To describe clinical and laboratory features of a cohort of patients with chronic myelogenous leukemia (CML) who developed Ph(-), trisomy 8(+) metaphases while on treatment with imatinib mesylate... - Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemiaNeil P Shah
Division of Hematology Oncology, University of California, San Francisco School of Medicine, Box 1270, 505 Parnassus Ave, San Francisco, CA 94143, USA
J Clin Oncol 26:3204-12. 2008..Once-daily treatment resulted in less toxicity, suggesting that toxicity results from continuous inhibition of unintended targets. Here, a dose- and schedule-optimization study is reported... - Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemiaR T Silver
The Leukemia and Myeloproliferative Disease Center, Division of Hematology Oncology, Weill Medical College of Cornell University, 525 East 68th Street, New York, NY 10021, USA
Leukemia 19:39-43. 2005.... - Direct evidence that Bcr-Abl tyrosine kinase activity disrupts normal synergistic interactions between Kit ligand and cytokines in primary primitive progenitor cellsAnnabel Strife
Molecular Pharmacology and Chemistry Program, Sloan Kettering Institute, New York, NY, USA
Mol Cancer Res 1:176-85. 2003.... - Polycythemia vera and other polycythemia syndromesRichard T Silver
Weill Cornell Medical University, New York, NY, USA
Cancer Treat Res 142:1-27. 2008 - Five-year follow-up of patients receiving imatinib for chronic myeloid leukemiaBrian J Druker
Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
N Engl J Med 355:2408-17. 2006..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy... - A hope for the futureRichard T Silver
Cancer Invest 21:486. 2003 - Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapyAndreas Hochhaus
III Medizinische Klinik, Medizinische Fakultat Mannheim, Universitat Heidelberg, Theodor Kutzer Ufer 1 3, 68167 Mannheim, Germany
Blood 109:2303-9. 2007..This trial was registered at www.clinicaltrials.gov as CA180013... - Novel tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia veraZeyu Xiong
Department of Pharmacology, Temple University School of Medicine, Philadelphia, PA 19140, USA
Clin Immunol 122:279-87. 2007.... - Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemiaMartin L Lesser
North Shore Long Island Jewish Research Institute, Manhasset, NY, USA
Cancer Genet Cytogenet 137:79-84. 2002..The results indicate that mixing data of different methods to measure treatment response within or between patients may be misleading clinical index... - Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2Jerry L Spivak
N Engl J Med 355:737; author reply 738. 2006 - A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasOliver G Ottmann
Medizinische Klinik III Abteilung Haematologie, Johann Wolfgang Goethe Universitat, 60590 Frankfurt, Germany
Blood 100:1965-71. 2002..Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib... - Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alphaAmy V Jones
Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, United Kingdom
Blood 107:3339-41. 2006..Our data indicate that, although PV patients may benefit from imatinib or rIFNalpha, molecular responses are relatively modest... - Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyMoshe Talpaz
M D Anderson Cancer Center, Houston, Texas, USA
Blood 99:1928-37. 2002..Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase. A daily dose of 600 mg is more effective than 400 mg, with similar toxicity... - Imatinib mesylate in polycythemia veraJerry L Spivak
Blood 103:3241; author reply 3241-2. 2004 - Characterization of murine JAK2V617F-positive myeloproliferative diseaseThomas G P Bumm
Center for Hematologic Malignancies, Oregon Health and Science University Cancer Institute, Portland, OR 97239, USA
Cancer Res 66:11156-65. 2006..The disease was not transplantable and prolonged observation showed normalization of blood counts in most JAK2(V617F) mice, suggesting that the mutation may not confer self-renewal capacity... - Treatment of polycythemia vera with recombinant interferonRichard T Silver
Department of Medicine Cornell University, New York Presbyterian Hospital, NY, USA
Int J Hematol 76:294-5. 2002 - The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposalJerry L Spivak
Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Blood 112:231-9. 2008 - Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research andRuben A Mesa
Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Leuk Res 31:737-40. 2007.... - Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha: a Cancer and Leukemia Group B studySherif S Farag
The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
Int J Oncol 25:143-51. 2004..We conclude that, with the possible exception of +8, +Ph and i(17)(q10), additional chromosomal abnormalities at diagnosis are not associated with inferior outcome in Ph+ CML patients treated with IFN-alpha-based therapy... - An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactionsZeyu Xiong
Department of Pharmacology, Temple University School of Medicine, 3420 North Broad Street, Philadelphia, PA 19140, USA
J Immunol 177:4907-16. 2006..The eliciting antitumor immune response against unconventional Ag MPD6 in patients with myeloproliferative diseases suggests MPD6 as a potential target of novel immunotherapy... - International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)Ayalew Tefferi
Mayo Clinic, 200 First Street SW, Rochester MN 55905, USA
Blood 108:1497-503. 2006..Bone marrow histologic and hematologic remissions characterize CR and CR/PR, respectively. The panel agreed that the CI response category is applicable only to patients with moderate to severe cytopenia or splenomegaly... - Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disordersAmy V Jones
Wessex Regional Genetics Laboratory, Salisbury District Hospital, Salisbury SP2 8BJ, United Kingdom
Blood 106:2162-8. 2005..We conclude that V617F is widespread in MPDs. Detection of this acquired mutation is likely to have a major impact on the way patients with MPD are diagnosed, as well as serving as an obvious target for signal transduction therapy... - Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay, for the detection of JAK2 V617F mutation in chronic myeloproliferative disordersQiaofang Chen
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, 1300 York Ave, New York, NY 10021, USA
J Mol Diagn 9:272-6. 2007..The assay is fast and easy to perform, and no special equipment other than thermocyclers is required. All these features make the assay readily and broadly applicable in clinical molecular diagnostic laboratories...